05/12/2026
What a week at !
🔑 Key takeaways:
Our CEO Emily Leproust kicked things off on the main stage with a panel fireside chat that traced a decade of building Twist after our first product launch in 2015 in London’s SynBioBeta.
The message was simple but powerful: what looks like an overnight success is really 11 years of relentless innovation, ex*****on and operational excellence. From our origins in DNA synthesis, to delivering on market and investor promises, building an innovation engine and expanding to NGS tools, and more recently expanding our footprint in proteins and AI-based drug discovery. Emily and John Cumbers’s discussion covered this journey and lessons learned while building it all.
→ Our CSO, Colby Souders, interacted with leaders from Atomic AI, Infinimmune, and Amazon Bio, exploring how Twist’s high-throughput data capabilities are growing and enabling pharma-scale discoveries in the “The Biology Data Flywheel” breakout session.
→ Our VP of R&D Esteban Toro joined NVIDIA, Oracle, and Cradle to highlight “The New Computational Biology Stack” and how tightly integrated design-build-test-learn cycles are reshaping therapeutic discovery and Twist’s role in enabling successes via wet-lab validation.
→ Our CEO, Emily Leproust joined a breakout panel on Breaking the Barriers of DNA Synthesis to formally introduce our new Complex Genes offering, designed to tackle previously hard-to-synthesize sequences at any scale and any complexity, affordably and reliably.
Our booth 117 invited founders, investors, pioneers from AI tech bio and biotech companies, academics and students who spent time networking with twisters, meeting our C-suite and Emily Leproust. The connections made here fuel the science we’re all building toward.
